Presentations on Ropeginterferon Alfa-2b During ASH Annual Meeting Highlight Momentum in the Care of Polycythemia Vera
Follow PharmaEssentia USA on Twitter and LinkedIn to get news and updates on our activity at the ASH Annual Meeting.
- Follow PharmaEssentia USA on Twitter and LinkedIn to get news and updates on our activity at the ASH Annual Meeting.
- PV may result in cardiovascular complications such as thrombosis and embolism, and often transforms to secondary myelofibrosis or leukemia.
- BESREMi has orphan drug designation for treatment of polycythemia vera (PV) in adults in the United States.
- Blast Transformation and Fibrotic Progression in Polycythemia Vera and Essential Thrombocythemia: A Literature Review of Incidence and Risk Factors.